GF Fund Management’s Travere Therapeutics TVTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$125K Buy
2,128
+173
+9% +$10.6K ﹤0.01% 319
2026
Q2
$111K Sell
1,955
-54
-3% -$2.39K ﹤0.01% 322
2026
Q1
$59.7K Buy
2,009
+252
+14% +$7.53K ﹤0.01% 379
2025
Q4
$67.1K Sell
1,757
-161
-8% -$5.24K ﹤0.01% 381
2025
Q3
$45.8K Sell
1,918
-280
-13% -$5.26K ﹤0.01% 401
2025
Q2
$32.5K Hold
2,198
– – ﹤0.01% 450
2025
Q1
$39.4K Buy
2,198
+395
+22% +$8.02K ﹤0.01% 442
2024
Q4
$31.4K Buy
+1,803
New +$31.9K ﹤0.01% 431

Other funds holding TVTX

GF Fund Management's TVTX Position: Q3 2026 in Review

GF Fund Management increased its Travere Therapeutics (TVTX) stake by 8.8% in Q3 2026, buying an estimated $10.6K and bringing the position to 2,128 shares worth $125K. The position accounts for ﹤0.01% of the portfolio, ranked #319.

GF Fund Management first reported a position in TVTX in Q4 2024 and has held it in 8 quarters since. 345 funds tracked by Wall St. Rank hold TVTX as of Q3 2026.

  • GF Fund Management held 2,128 shares of Travere Therapeutics worth $125K as of Q3 2026.
  • GF Fund Management bought 173 Travere Therapeutics shares in Q3 2026, an estimated $10.6K.
  • Travere Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q3 2026, its #319 holding.
  • GF Fund Management first reported a position in Travere Therapeutics in Q4 2024 and has held it in 8 quarters since.
  • 345 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2026.

Based on GF Fund Management's 13F filing for Q3 2026, filed 26 Oct 2026.